ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SKYE Skye Bioscience Inc

10.94
-0.38 (-3.36%)
Jun 07 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 46,877
Bid Price 9.91
Ask Price 11.88
News -
Day High 11.25

Low
10.50

52 Week Range

High
17.6473

Day Low 10.70
Company Name Stock Ticker Symbol Market Type
Skye Bioscience Inc SKYE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.38 -3.36% 10.94 17:51:37
Open Price Low Price High Price Close Price Prev Close
11.00 10.70 11.25 10.94 11.32
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,648 46,877 $ 10.96 $ 513,904 - 10.50 - 17.6473
Last Trade Time Type Quantity Stock Price Currency
16:00:03 formt 285 $ 10.94 USD

Skye Bioscience Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
359.55M 28.07M - 152k -37.65M -1.34 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Skye Bioscience News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SKYE Message Board. Create One! See More Posts on SKYE Message Board See More Message Board Posts

Historical SKYE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.7212.1610.5011.6066,895-0.78-6.66%
1 Month12.5813.4410.5011.8855,760-1.64-13.04%
3 Months13.5017.647310.5013.2260,467-2.56-18.96%
6 Months13.5017.647310.5013.2260,467-2.56-18.96%
1 Year13.5017.647310.5013.2260,467-2.56-18.96%
3 Years13.5017.647310.5013.2260,467-2.56-18.96%
5 Years13.5017.647310.5013.2260,467-2.56-18.96%

Skye Bioscience Description

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.

Your Recent History

Delayed Upgrade Clock